Reviewing Daxor (NASDAQ:DXR) & Fresenius SE & Co. (OTCMKTS:FSNUY)

Daxor (NASDAQ:DXR) and Fresenius SE & Co. (OTCMKTS:FSNUY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Valuation & Earnings

This table compares Daxor and Fresenius SE & Co.”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Fresenius SE & Co.	$23.63 billion	N/A	$509.67 million	$0.53	25.96

Fresenius SE & Co. has higher revenue and earnings than Daxor.

Volatility & Risk

Daxor has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, Fresenius SE & Co. has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Insider & Institutional Ownership

1.3% of Daxor shares are held by institutional investors. 59.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Daxor and Fresenius SE & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Fresenius SE & Co.	5.09%	9.33%	4.31%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Daxor and Fresenius SE & Co., as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	0	1	0	3.00
Fresenius SE & Co.	0	0	2	1	3.33

Daxor presently has a consensus target price of $25.00, indicating a potential upside of 114.41%. Given Daxor’s higher possible upside, research analysts clearly believe Daxor is more favorable than Fresenius SE & Co..

Summary

Fresenius SE & Co. beats Daxor on 8 of the 11 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About Fresenius SE & Co.

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.